Ginkgo agrees to $17.5b merger with Harry Sloan's SPAC : vim

Ginkgo agrees to $17.5b merger with Harry Sloan's SPAC


Ginkgo agrees to $17.5b merger with Harry Sloan’s SPAC
By Gillian Tan, Crystal Tse and Kristen V. Brown Bloomberg,Updated May 11, 2021, 7:31 a.m.
Email to a Friend
An automated fermenting machine at the Ginkgo Bioworks Inc. facility in Boston.Scott Eisen/Bloomberg
Ginkgo Bioworks Inc., which calls itself an “organism design” company, has agreed to go public in a $17.5 billion merger with a blank-check firm backed by former Hollywood executive Harry Sloan.
The Boston-based company, which uses technology to program cells for a potentially wide variety of uses, will combine with Soaring Eagle Acquisition Corp., according to a regulatory filing Tuesday that confirmed an earlier Bloomberg News report.

Related Keywords

Tom Knight , Arie Belldegrun , Jason Kelly , Kite Pharma Inc , Allogene Therapeutics Inc , Massachusetts Institute Of Technology , Kite Pharma , Soaring Eagle , Massachusetts Institute , Cascade Investment , Viking Global Investors , டோம் நைட் , ஜேசன் கெல்லி , காத்தாடி பார்மா இன்க் , மாசசூசெட்ஸ் நிறுவனம் ஆஃப் தொழில்நுட்பம் , காத்தாடி பார்மா , உயரும் கழுகு , மாசசூசெட்ஸ் நிறுவனம் , அடுக்கை முதலீடு , வைக்கிங் உலகளாவிய முதலீட்டாளர்கள் ,

© 2025 Vimarsana